Biotechnology companies apply biological science to develop products, services and technologies that address challenges in healthcare, agriculture, industry and environmental sustainability.
This category includes companies working on:
Browse 360 UK biotechnology companies below.
Next-generation programmable gene insertion platform technology
Gene Weaver is a preclinical-stage biotechnology company developing a programmable, RNA-based gene insertion platform. Its RNA-guided enzymatic system functions as a complete molecular machine, locating the target site and inserting large DNA payloads to enable kilobase-scale gene insertion at virtually any genomic…
Non-viral intracellular delivery platform based on biomolecular condensates
PartitionBio is a biotechnology company developing a non-viral intracellular delivery platform based on liquid-liquid phase separation and biomolecular condensates. Its lead product, BubbleFect, is a room-temperature-stable, non-lipid reagent designed for bench-top use without specialist equipment or cold-chain…
Near-infrared bioluminescence reagents for preclinical imaging research
Bioflares is a biotechnology company developing and supplying infraluciferin-based reagents and engineered luciferase enzymes for near-infrared bioluminescence imaging. Its patented infraluciferin substrate enables simultaneous dual-parameter imaging of two biological processes in living animals, supporting…
Small molecule drug discovery targeting rare genetic diseases and oncology
Tay Therapeutics is a drug discovery company developing targeted small molecule therapies for rare genetic diseases and cancer. Its platform uses stop codon read-through technology to restore production of functional proteins disrupted by premature stop codon mutations, with programmes targeting oncology, cystic…
Drug discovery platform targeting biomolecular condensates
Transition Bio is a biotechnology company developing a drug discovery platform based on the biology of biomolecular condensates, the membrane-less cellular structures implicated in a range of diseases. Using droplet microfluidics and machine learning, the company maps and modulates condensate behaviour to identify…
Silica encapsulation platform eliminating cold chain for biologics
EnsiliTech is a biotechnology company developing ensilication, a patented platform technology that encases vaccines, antibodies, and other biologics within a silica matrix to render them thermally stable without refrigeration. The technology is applicable to existing and new biopharmaceutical formulations, enabling…
Surface acoustic wave nebuliser platform for inhaled drug delivery
Nebu~Flow is a UK medical technology company developing next-generation nebuliser devices using patented surface acoustic wave technology to aerosolise drugs into precisely controlled droplet sizes for deep lung deposition. The platform is designed to enable inhalation delivery of biologics, RNA-based formulations,…
One-step encapsulation drug delivery platform for advanced therapeutics
PNAS Therapeutics is a UK-based drug delivery company developing a one-step encapsulation platform designed to simplify complex pharmaceutical manufacturing processes. The platform enhances local delivery through improved bioavailability and targeting, is compatible with multiple active pharmaceutical ingredients, and…
Discovery platform targeting therapy-induced antigens driving cancer relapse
Errigal Bio is an oncology-focused drug discovery company developing a platform that identifies therapy-induced antigen targets arising in cancer cells that survive standard treatment. The company's approach is based on the premise that these surviving tumour cells carry exploitable vulnerabilities created by the…
Human iPSC platform for neurodegenerative disease drug discovery
Talisman Therapeutics is a drug discovery company specialising in human induced pluripotent stem cell (iPSC) models of neurodegenerative disease. The company operates both an internal discovery pipeline, focused on Alzheimer's disease targets including lysosome biology, pathogenic protein reduction and microglial…
High-sensitivity lateral flow diagnostics for point-of-care testing
SwiftDx is a Cambridge-based diagnostics company developing a next generation of high-sensitivity lateral flow assays using proprietary eAMP (enhanced Amplification) and DNA detection technologies. Its platform enables detection of targets undetectable by conventional lateral flow tests, without requiring specialist…
Small-molecule HO-1 inhibitors to overcome chemotherapy resistance in tumours
Aethox Therapeutics is a preclinical biotechnology company developing small-molecule drugs that help solid tumours respond to chemotherapy and other standard cancer treatments. Its lead approach targets heme oxygenase-1 (HO-1), an enzyme produced by tumour-associated macrophages that can block cancer-fighting T cells…
Synthetic chromosome engineering for crop plants
Syntato is a plant biotechnology company applying synthetic biology to design and build plant chromosomes. The company aims to make chromosomes modular and reusable so that adaptive traits can be added as single units while the native genome is preserved. It combines synthetic biology, automation and protein design,…
Clinical-stage CNS drug discovery using human brain genomics
Cerevance is a clinical-stage biotechnology company developing small molecule therapeutics for neurodegenerative and psychiatric disorders. The company uses its proprietary platform to profile gene expression in specific neuronal and glial cell types from a collection of over 16,000 annotated human brain tissue…
Stem-cell disease models and multi-omics toxicology platforms
Stemnovate is a Cambridge biotechnology company developing human stem-cell models and multi-omics platforms for drug discovery and toxicology. Its induced pluripotent stem cell biobank supports reprogramming, differentiation and the development of disease-relevant cellular models. Genomic, transcriptomic, proteomic…
Synthetic promoter platform for precision gene expression control
Chromatin Bioscience designs synthetic promoters and gene expression control systems for cell and gene therapy developers. Its platform uses bioinformatics to identify cell-type-selective regulatory elements from the human genome, which are assembled into novel synthetic promoters enabling precise, durable and…
Curative genetic medicines for peripheral nerve diseases
CureAge Therapeutics develops genetic medicines for peripheral nerve disorders, initially targeting neurofibromatosis type 1 (NF1). Its investigational platform uses locally delivered lipid nanoparticles to carry genetic material into Schwann cells, aiming to restore NF1 gene function and address surrounding tumour…
Thermostable vaccine formulations delivered through microneedle patches
Microneedle Solutions is a biotechnology company developing vaccine-containing microneedle patches for self-administration. Its platform combines a patented needle-array manufacturing process with vaccine-loaded matrices intended to protect biological payloads and enable delivery through the skin. The company has…
Electrochemical lateral flow diagnostics for accessible at-home health testing
éclateral is a UK-based developer of electrochemical lateral flow diagnostic technology for at-home and point-of-care testing. The company's portable reader pairs with adapted lateral flow test cassettes and a companion mobile app to deliver quantitative, sensitive results beyond standard optical lateral flow…
Selective gluten-degrading enzymes for wheat-based food production
Prozymi Biolabs is an Edinburgh biotechnology company developing enzymes that selectively degrade immunogenic gluten peptides in wheat-based foods. Its technology aims to reduce sequences associated with coeliac immune responses while retaining the gluten functionality needed for bread texture. It targets conventional…